Antithrombin III Prevents Cerulein-Induced Acute Pancreatitis in Rats

Hagiwara, Satoshi; Iwasaka, Hideo; Shingu, Chihiro; Matsumoto, Shigekiyo; Uchida, Tomohisa; Noguchi, Takayuki

doi:10.1097/mpa.0b013e3181aba9fa

Cited by 29 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pretreatment with antithrombin was shown to ameliorate cerulein-induced AP in rats [200]. Edema, inflammation and necrosis of the pancreas were partially reduced and serum concentrations of IL-6, TNF-α, and high-mobility box group 1 protein were diminished in mice pretreated with antithrombin.…”

Section: Therapeutic Effects Of Anticoagulants In Acute Pancreatitismentioning

confidence: 99%

The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications

Dumnicka

Maduzia

Ceranowicz

et al. 2017

IJMS

154

113

View full text Add to dashboard Cite

Acute pancreatitis (AP) is an inflammatory disease with varied severity, ranging from mild local inflammation to severe systemic involvement resulting in substantial mortality. Early pathologic events in AP, both local and systemic, are associated with vascular derangements, including endothelial activation and injury, dysregulation of vasomotor tone, increased vascular permeability, increased leukocyte migration to tissues, and activation of coagulation. The purpose of the review was to summarize current evidence regarding the interplay between inflammation, coagulation and endothelial dysfunction in the early phase of AP. Practical aspects were emphasized: (1) we summarized available data on diagnostic usefulness of the markers of endothelial dysfunction and activated coagulation in early prediction of severe AP; (2) we reviewed in detail the results of experimental studies and clinical trials targeting coagulation-inflammation interactions in severe AP. Among laboratory tests, d-dimer and angiopoietin-2 measurements seem the most useful in early prediction of severe AP. Although most clinical trials evaluating anticoagulants in treatment of severe AP did not show benefits, they also did not show significantly increased bleeding risk. Promising results of human trials were published for low molecular weight heparin treatment. Several anticoagulants that proved beneficial in animal experiments are thus worth testing in patients.

show abstract

Section: Therapeutic Effects Of Anticoagulants In Acute Pancreatitismentioning

confidence: 99%

The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications

Dumnicka

Maduzia

Ceranowicz

et al. 2017

IJMS

154

113

View full text Add to dashboard Cite

show abstract

“…In taurocholate-induced experimental pancreatitis in rats, high dose AT treatment was shown to improve survival (Bleeker et al, 1992). In cerulein-induced AP, AT supplementation inhibited the release of high mobility group box 1 protein (HMGB1) as well as other proinflammatory cytokines in rats (Hagiwara et al, 2009). However, in a systematic review of randomized trials, AT seems ineffective in improving overall mortality in critically ill patients (Afshari et al, 2007).…”

Section: Antithrombin In Apmentioning

confidence: 99%

Coagulation Abnormalities in Acute Pancreatitis

Gould¹,

Mai²,

Liaw³

2012

Pancreatitis - Treatment and Complications

View full text Add to dashboard Cite

“…ATIII (500 μg/kg) or an equivalent volume of vehicle was intravenously delivered 30 min before or after CIN. The ATIII dose used to reduce kidney injury was chosen based on a previous study (Hagiwara et al, 2009). The animals were killed 24 h or 36 h after induction of CIN.…”

Section: Methodsmentioning

confidence: 99%

Antithrombin III Protects Against Contrast-Induced Nephropathy

Cheng

Yin

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

We previously reported that insufficiency of antithrombin III (ATIII), the major anti-coagulation molecule in vivo, exacerbated renal ischemia-reperfusion injury in animal models and possibly humans. In the present study, we investigated the relationship between ATIII level and contrast induced nephropathy (CIN) in patients and examined therapeutic effect of ATIII on CIN in Sprague-Dawley rats. Patients with low ATIII activity presented a higher incidence of acute kidney injury (AKI) following coronary angiography. ATIII (500 μg/kg) was intravenously injected before or after the induction of AKI in rats. Our data demonstrated ATIII significantly attenuated the elevation of serum creatinine, blood urea nitrogen, and renal histological injury. The beneficial effects of ATIII were accompanied by diminished renal inflammatory response, oxidative stress, cell apoptosis and improved renal blood flow in rats. In conclusion, ATIII appears to attenuate CIN through inhibiting inflammation, oxidative stress, apoptosis and improving renal blood flow. ATIII administration may represent a promising strategy for the prevention and treatment of contrast-induced AKI.

show abstract

Antithrombin III Prevents Cerulein-Induced Acute Pancreatitis in Rats

Abstract: Antithrombin III treatment inhibited the secretion of cytokines, NO, and HMGB1 and prevented cerulein-induced acute pancreatitis in the rat model.

Cited by 29 publications

References 27 publications

The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications

The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications

Coagulation Abnormalities in Acute Pancreatitis

Antithrombin III Protects Against Contrast-Induced Nephropathy

Contact Info

Product

Resources

About